Section 01
What it's used for
Wrinkle reduction, trial vs claims
In a 12-week trial of 93 women, topical Matrixyl reduced wrinkles vs placebo, but no exact percentage was given. The widely cited 68% wrinkle and 350% collagen figures come from unpublished maker data on a different blend, Matrixyl 3000.
▸Clinical wording
A double-blind, placebo-controlled, split-face clinical trial in 93 women found that topical palmitoyl pentapeptide (Matrixyl) significantly improved wrinkles and fine lines after 12 weeks of use compared with placebo, though the published trial does not report a specific percentage reduction. The commonly cited figures of a 68% reduction in wrinkle depth and a 350% increase in collagen I/III synthesis trace to unpublished manufacturer data for the related Matrixyl 3000 blend (a two-peptide formulation tested over 6 months) and are not confirmed in peer-reviewed literature.
Signals that speed skin repair
Matrixyl mimics matrikines — collagen fragments released after skin injury that signal skin cells to speed up repair. Researchers are studying whether this signaling accelerates the skin's natural healing process.
▸Clinical wording
Matrikine signaling accelerates dermal repair.
Section 02
Mechanism of Action
An offcut that signals build more
- When collagen fibres assemble, end pieces are trimmed off and act as feedback messages to the cell.
- One trimmed fragment boosted matrix production in cell culture, and researchers narrowed it to five building blocks.
- Matrixyl is that five-part fragment with a fatty acid attached to one end.
▸Clinical wording
Procollagen I C-propeptide matrikine feedback
The amino- and carboxy-terminal propeptides of fibril-forming collagens are cleaved off extracellularly during fibril assembly and have long been implicated in feedback regulation of collagen synthesis. A subfragment of the type I procollagen C-propeptide, residues 197-241, was shown to augment extracellular matrix production in subconfluent fibroblasts. Systematic dissection of that fragment identified Lys-Thr-Thr-Lys-Ser (KTTKS, residues 212-216) as the minimum sequence retaining potent stimulation across mesenchymal cell types. Matrixyl is this pentapeptide with palmitic acid amide-linked to the N-terminal lysine.
More matrix in dishes and skin
- In cell culture the fragment raised two collagen types and a structural protein without lifting total protein output.
- The effect appeared only in sparse cultures and disappeared once the cells grew crowded.
- Later groups repeated the collagen result in human and mouse skin cells.
- In a 12-week trial in 93 women, a cream with it reduced fine lines against the plain base.
▸Clinical wording
Extracellular matrix output in fibroblasts and photoaged skin
In the original fibroblast work KTTKS raised production of type I collagen, type III collagen and fibronectin in a dose- and time-dependent way, without changing total protein synthesis or the ratio of secreted to cell-associated protein. The effect was density-dependent, present in subconfluent cultures and lost at confluence. Later work reproduced collagen stimulation in human dermal fibroblasts by soluble-collagen assay and in murine 3T3-NIH fibroblasts by Sirius Red staining. In a 12-week double-blind split-face trial in 93 women, a moisturiser carrying pal-KTTKS reduced fine lines and wrinkles against the vehicle by image analysis and expert grading.
The missing receptor and a partial answer
- No one has found the cell receptor this fragment binds to, so the mechanism stays open.
- In rat tendon cells it raised collagen output and the level of a growth factor (TGF-β).
- The authors read that growth factor as an amplifier the cell makes for itself.
- That evidence comes from tendon rather than skin and does not show direct receptor binding.
▸Clinical wording
TGF-β upregulation as a downstream amplifier
How fibroblasts read the KTTKS signal is not resolved; no receptor for the pentapeptide has been identified in the primary literature. One partial answer comes from rat Achilles tendon cells, where KTTKS increased type I collagen expression, slowed degradation of α1(I) procollagen mRNA and raised TGF-β concentration in a dose-dependent way, which the authors read as collagen induction proceeding through TGF-β upregulation. That places TGF-β downstream of the peptide as an autocrine amplifier; it is not evidence that KTTKS binds TGF-β receptors, and the model is tendon rather than dermis.
Why the fatty tail was added
- The fatty acid matches a lipid already abundant in the outer skin layer and improves penetration.
- It also makes the molecule clump into ribbon-like structures resolved by electron microscopy and X-ray scattering.
- Activity in cultured cells rose around the concentration where clumping starts, so the two seem coupled.
- Clumping in water can also lower the available peptide, which fatty capsules are used to offset.
▸Clinical wording
Palmitoyl chain, amphiphilicity and self-assembly
Palmitic acid was chosen because it is among the most abundant lipids of the stratum corneum, and lipidation raises permeability relative to unmodified KTTKS. It also makes the molecule an amphiphile that self-assembles: C16-KTTKS forms bilayer nanotapes that bundle into fibrils, resolved by cryo-TEM and small-angle X-ray scattering, and converts to micelles on heating. Collagen stimulation in human dermal and corneal fibroblasts rose with concentration around the critical aggregation concentration measured by pyrene fluorescence, so assembly state and activity appear coupled. In aqueous media that same aggregation can lower available peptide, which liposomal encapsulation counters.
Holding back the scar-forming cell type
- Repair cells can convert into a contracting form that pulls wounds tight and drives raised scars.
- In human cell culture the peptide reduced that conversion and the contraction of a collagen gel.
- Lower concentrations worked better than higher ones in this assay.
- The authors describe a balance: it supports matrix production while damping the scar-forming conversion.
▸Clinical wording
Myofibroblast differentiation and wound contraction
The same matrikine signal touches the contractile side of repair. In human fibroblasts, pal-KTTKS reduced alpha-smooth-muscle-actin expression and the trans-differentiation of fibroblasts into myofibroblasts in a concentration-dependent manner, assessed by western blot for α-SMA and connective tissue growth factor alongside a three-dimensional collagen lattice contraction assay; lower concentrations were more effective than higher ones. The authors frame this as a balance to be managed, since the peptide supports matrix production while damping the myofibroblast conversion that drives hypertrophic scarring.
Section 03
Biological Pathways
- Procollagen Matrikine SignalMatrixyl is KTTKS, the minimum active fragment of the procollagen C-propeptide, palmitoylated for skin penetration; in subconfluent fibroblasts it raises type I/III collagen and fibronectin output dose-dependently.
- TGF-β Autocrine AmplificationNo receptor for KTTKS is identified; in rat tendon cells the pentapeptide raised TGF-beta levels alongside collagen expression, suggesting amplification downstream via TGF-beta rather than direct receptor binding.
- Palmitoyl Self-AssemblyThe palmitic acid tail makes pal-KTTKS an amphiphile that self-assembles into bilayer nanotapes and fibrils; collagen stimulation rises near the critical aggregation point, linking assembly state to activity.
- Myofibroblast RestraintPal-KTTKS reduces alpha-smooth-muscle-actin expression and fibroblast-to-myofibroblast conversion dose-dependently, damping the contractile trans-differentiation behind hypertrophic scarring during wound repair.
Section 04
Dosage Information
Pal-Lys-Thr-Thr-Lys-Ser (palmitoyl pentapeptide-4)| Route / system | Context | Range studied | Limitation |
|---|---|---|---|
| Topical — the main trial | Double-blind split-face trial, 2005 | 3 ppm of the peptide (0.0003%) in a moisturiser, twice daily for 12 weeks; 93 women aged 35–55, fewer wrinkles than the cream alone | One strength in one cream: nothing above 3 ppm was tested, so a bigger label number has no trial behind it. The study was run by the peptide's co-developer. |
| Topical — what the label percent means | Cosmetic labels quoting a "Matrixyl" percentage | Matrixyl raw material holds over 90–100 ppm peptide and goes in at 3–8% of a formula: about 3–8 ppm in the jar — 0.0003–0.0008% | "5% Matrixyl" is 5% of a solution over 99.98% diluent. The peptide figure is four orders of magnitude smaller and rarely printed, so labels cannot be compared. |
| Topical — against retinol | Split-face comparison, peptide versus retinol | 3 ppm of the peptide against 700 ppm (0.07%) retinol: similar wrinkle improvement, with less irritation, redness and sun sensitivity | 0.07% is a weak retinol, so the bar was low. Matching it on wrinkle scores says nothing about matching a prescription retinoid such as tretinoin. |
| Topical — independent randomised trial | Double-blind trial against placebo, crow's feet, 2023 | Peptide cream twice daily for 8 weeks in 21 women, seven per arm; crow's-feet grading fell 0.86 points, static and dynamic | Seven per arm, and the device readings — moisture, water loss, elasticity — missed significance (p > 0.05). With no stated strength it cannot be repeated. |
Section 05
Protocols
- Protocol 01
Anti-Aging Skincare Peptide Stack
Topical peptide protocol for wrinkle reduction, collagen stimulation, and skin rejuvenation.
- Focus
- Skin & Beauty
- Level
- Beginner
- Duration
- 8–12 weeks
Section 06
Stability & Storage
Storing the product
Matrixyl (a palmitoyl pentapeptide) is stable in cosmetic formulations at pH 5-7 and is kept at room temperature. Its palmitoyl chain gives it lipophilic stability, and it is compatible with most other cosmetic ingredients.
After opening
Once a formulation containing Matrixyl is opened, it is kept tightly closed, away from heat and direct light, to limit oxidation and pH drift; exact stability after opening depends on the specific formulation and packaging.
Section 07
Side Effects & Precautions
Matrixyl (palmitoyl pentapeptide-4) has a cosmetic-safety review that is still a draft, and every irritation, sensitization, and eye-safety study behind it is unpublished 1999 industry data. The often-cited "2-8%" figure describes the supplier's raw-material solution, not the peptide itself.
"2-8%" describes the solution, not the peptide
The Matrixyl trade solution is 100 ppm (0.01%) peptide; "2-8%" is that solution's dilution rate. At 3% dilution, this gives about 3 parts per million of peptide, the level used in the main clinical study. Tolerance tests used 0.01%, 0.018%, and once 0.12% peptide - never near 2-8%.
Review is still a draft, all data unpublished
The safety assessment is still a draft final report, unpublished. Every irritation, sensitization, and eye-safety study behind it is unpublished 1999 industry data submitted for the manufacturer. The only peer-reviewed human data is one published tolerability observation at 3 parts per million.
Sensitization data is one small, undetailed test
- The "non-sensitizing" conclusion rests on one patch test of 51 people using a 0.01%-peptide trade mixture; the record states no further details were provided.
- A separate animal test used guinea pigs at 0.01%.
- In a different 10-person irritation test, 1 subject showed very slight redness, though the material was rated well tolerated overall.
- No published reports of allergic contact dermatitis to this peptide were found, though no dedicated surveillance was found either.
Tolerance testing did not include sensitive skin
Clinical tolerance data come from general cosmetic-use groups: 93 healthy women aged 35-55 in one study, and a separate study of 196 women at an unspecified concentration. No study in sensitive, reactive, or atopic skin was found, and reviewers drew no conclusion about sensitive skin.
The peptide does reach the deeper skin layers
Attaching a fat chain to this peptide makes it fat-soluble, unlike the unmodified form. In a lab skin model, 14.6% of the applied dose stayed in the skin, including some in the dermis. A trace also reached the fluid beneath the skin at 24 hours, below the amount the test could precisely measure.
Section 08
Regulatory Status
Like other peptide actives sold in anti-aging skincare, it is regulated as a cosmetic component under US and EU law, and no drug regulator has evaluated or approved it for any therapeutic use.
FDA / United States
Cosmetic ingredient, no pre-market approval
Under the FD&C Act, Palmitoyl Pentapeptide-4 (pal-KTTKS) is regulated as a cosmetic and needs no FDA review before sale. FDA's 2023 Voluntary Cosmetic Registration Program data lists it in 239 formulations, most of them leave-on skincare.
EU
Governed by Regulation (EC) 1223/2009
It is entered in the CosIng database as a skin-conditioning agent; because it is not a restricted substance, no SCCS opinion is required. A 2024 Cosmetic Ingredient Review safety assessment of the pentapeptide group concluded it is safe as currently used.
Claims boundary
Wording, not the peptide, decides the category
FDA has sent warning letters over claims that a product will "enhance the production of elastin and collagen in the skin" — the same collagen-synthesis story used to market Matrixyl. Making that claim about structural change risks drug, not cosmetic, classification.
WADA
Not on the Prohibited List
Palmitoyl Pentapeptide-4 is a topical skin-conditioning peptide, not a hormone or growth factor, so it sits outside category S2 and carries no sport-specific restriction.
This status covers Matrixyl as a topical cosmetic ingredient used at the concentrations reviewed above; claims that go further — treating a disease, or promising to change skin structure — move a product into drug regulation regardless of the label. Regulatory status differs between jurisdictions and can change — check the current rules of your own regulator.
Section 09
Research Studies
- [1]A pentapeptide from type I procollagen promotes extracellular matrix productionKatayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. · Journal of Biological Chemistry · 1993
- [2]Topical palmitoyl pentapeptide provides improvement in photoaged human facial skinRobinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. · International Journal of Cosmetic Science · 2005
- [3]The pentapeptide KTTKS promoting the expressions of type I collagen and transforming growth factor-β of tendon cellsTsai WC, Hsu CC, Chung CY, Lin MS, Li SL, Pang JS. · Journal of Orthopaedic Research · 2007
- [4]Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblastsJones RR, Castelletto V, Connon CJ, Hamley IW. · Molecular Pharmaceutics · 2013
- [5]Liposome encapsulation of the palmitoyl-KTTKS peptide: structural and functional characterizationVitali A, Paolicelli P, Bigi B, Trilli J, Di Muzio L, Carriero VC, Casadei MA, Petralito S. · Pharmaceutics · 2024
- [6]Boosting cosmeceutical peptides: coupling imidazolium-based ionic liquids to pentapeptide-4 originates new leads with antimicrobial and collagenesis-inducing activitiesGomes A, Bessa LJ, Fernandes I, Aguiar L, Ferraz R, Monteiro C, Martins MCL, Mateus N, Gameiro P, Teixeira C, Gomes P. · Microbiology Spectrum · 2022
- [7]Effect of palmitoyl-pentapeptide (Pal-KTTKS) on wound contractile process in relation with connective tissue growth factor and α-smooth muscle actin expressionPark H, An E, Cho Lee AR. · Tissue Engineering and Regenerative Medicine · 2017
Section 10
Frequently Asked Questions
One double-blind, placebo-controlled, split-face trial in 93 women found it significantly improved wrinkles and fine lines over 12 weeks, though the published trial doesn't report a specific percentage. The often-repeated "68% wrinkle reduction" and "350% more collagen" figures trace back to unpublished manufacturer data for a different, later formulation (Matrixyl 3000), not to peer-reviewed results for Matrixyl itself.
In a split-face comparison, 3 ppm of the peptide produced wrinkle improvement similar to 700 ppm (0.07%) retinol, with less irritation and sun sensitivity. That retinol concentration is on the weak end, though — matching it says nothing about how Matrixyl would compare with a prescription retinoid like tretinoin, which wasn't tested.
This isn't addressed in the sourced material — no ingredient-interaction study for Matrixyl with retinol, vitamin C, or niacinamide was found. What is documented is that Matrixyl is stable at pH 5–7 and described as compatible with most other cosmetic ingredients in formulation, which is a stability note rather than a tested combination result.
Pregnancy safety isn't covered in the sourced material. What is documented is a general safety profile — no irritation at standard 2–8% formulation concentrations and suitability for sensitive skin — but that comes from cosmetic-tolerability testing, not a pregnancy-specific study.
The main clinical evidence comes from measurements at fixed checkpoints, not a day-by-day timeline: the primary trial measured improvement at 12 weeks, and a smaller, independent placebo-controlled trial measured a wrinkle-grading improvement at 8 weeks. No study reports when the effect first becomes noticeable before those points.
Very little on its own. Matrixyl raw material is typically 90 to 100 ppm active peptide and gets added at 3 to 8% of a formula, which works out to roughly 3 to 8 ppm of actual peptide in the jar — about 0.0003 to 0.0008%. A "5% Matrixyl" label refers to the diluted raw-material blend, not 5% pure peptide, so label percentages across brands aren't directly comparable.
The sourced trials report no irritation at standard concentrations (2–8%) and describe it as non-sensitizing and suitable for sensitive skin. Purging or acne specifically isn't addressed in this material — the safety data available covers irritation and sensitization testing, not breakout risk.